Clinical Trial Update: Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating letrozole combined with anlotinib hydrochloride for platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Letrozole (letrozole)

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | Status: UNKNOWN